-
Mashup Score: 0Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 4Dr. Saad on ARASENS trial: “We now have evidence that we can do better in lethal prostate cancer” - 2 year(s) ago
“I think we need to change the mindset that chemotherapy is a bad thing. It is a very good thing when given appropriately and when patients are more likely to get long-term benefit,” says Fred Saad, MD, FRCS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Saad on ARASENS trial: “We now have evidence that we can do better in lethal prostate cancer” https://t.co/8I04tZOATz @chumontreal @CRCHUM #ProstateCancer #Darolutamide #Urology #Urologist
-
-
Mashup Score: 0
“If you’re going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
What makes the ARASENS trial so "game-changing" for mHSPC? https://t.co/YoOu7BMpmN #ProstateCancer #Urology #Urologist #Darolutamide
-
-
Mashup Score: 0ARASENS trial: Darolutamide improves survival in metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we’re doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Darolutamide improves survival in metastatic hormone-sensitive prostate cancer, study shows https://t.co/8gnY5cPTTt #Darolutamide #MHSPC #ProstateCancer #Urology #Urologist
-
-
Mashup Score: 0Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Fizazi discusses major findings from the phase 3 ARASENS trial https://t.co/gjWqI9T8C7 #Darolutamide #Urology #ProstateCancer #MHSPC #Urologist
-
-
Mashup Score: 0Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer https://t.co/PO3O9Xcs5i #ProstateCancer #Darolutamide #MHSPC #Urology #Urologist
-
-
Mashup Score: 0ARASENS trial: Darolutamide improves survival in metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we’re doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Saad on survival improvement in mHSPC with darolutamide https://t.co/P6WNL52UhM #Darolutamide #MHSPC #ProstateCancer #Urology #Urologist
-
-
Mashup Score: 0FDA approval sought for darolutamide in mHSPC - 2 year(s) ago
The filing is based on findings from the placebo-controlled phase 3 ARASENS trial.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
FDA approval sought for darolutamide plus docataxel in patients with mHSPC https://t.co/yc0cIqR1nX #Darolutamide #Docataxel #ProstateCancer #Urology #Urologist
-
-
Mashup Score: 0ARASENS trial: Darolutamide improves survival in metastatic hormone-sensitive prostate cancer - 2 year(s) ago
“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we’re doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
ARASENS trial: Darolutamide improves survival in metastatic hormone-sensitive prostate cancer https://t.co/fWT58O2Uao @chumontreal @CRCHUM #Darolutamide #MHSPC #ProstateCancer #Urology #Urologist
-
-
Mashup Score: 2
“If you’re going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Phase 3 ARASENS trial is "undoubtedly game-changing," says expert https://t.co/VJ5CnF8CYp #Darolutamide #Docetaxel #MHSPC #ProstateCancer #Urology #Urologist
-
Darolutamide-based triplet regimen shows promise for mHSPC, study finds https://t.co/YNrdb8nRfe #MHSPC #ProstateCancer #Darolutamide #Urology #Urologist